Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer · SE
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, and Liver Disease and Transplantation.
Semaglutide in MASH: A Promising Step Forward With Room for Improvement.
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.
Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort
Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies
The barriers to uptake of artificial intelligence in hepatology and how to overcome them
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
Incidence and Clinical Significance of Recompensation After HCV Cure
The barriers to uptake of artificial intelligence in hepatology and how to overcome them.
Prognostic Virological and Immunological Profiles in HBV-Related Acute Liver Failure.
HBcrAg and cirB-RNA Do Not Predict Clinical and Virological Outcomes in Patients With HBeAg-Negative Chronic Infection.
Simvastatin and Rifaximin for Decompensated Cirrhosis: A Hope Unfulfilled.
Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal.
HBV Suppression by Nucleos(t)ide Analogues Reduces PD-1 Expression on Liver-Resident T Cells.
EASL position paper on clinical follow-up after HCV cure
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)
Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital.
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis.
Resmetirom for Non-alcoholic Steatohepatitis.
In Search of the Best Second-Line Therapy for Primary Biliary Cholangitis.
Successful HCV Viral Cure Is Not the End of the Story.
The relevance of finding biomarkers to identify the best candidates for nucleos(t)ide analogue discontinuation in HBeAg-negative chronic hepatitis B.
miRNA Expression and HCC Occurrence in HCV Cirrhotic Patients Treated with Direct Acting Antivirals
Tissue CD14+CD8+ T cells reprogrammed by myeloid cells and modulated by LPS
Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response.
Bepirovirsen-A New Therapy for Chronic Hepatitis B Infection.
Low risk of viral hepatitis amongst patients with severe mental disorders.
Bulevirtide for Chronic Hepatitis Delta.